Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease

British Journal of Pharmacology

Volumn 141, Issue 4, 2004, Pages 689-697

  Toulmond, Sylvie ^a   Tang, Keith ^a   Bureau, Yves ^a   Ashdown, Helen ^a   Degen, Sarah ^a   O'Donnell, Ruth ^b   Tam, John ^a   Han, Yongxin ^a   Colucci, John ^a   Giroux, André ^a   Zhu, Yanxia ^a   Boucher, Mathieu ^a   Pikounis, Bill ^c   Xanthoudakis, Steven ^a   Roy, Sophie ^a   Rigby, Michael ^b   Zamboni, Robert ^a   Robertson, George S ^a   Ng, Gordon Y K ^a   Nicholson, Donald W ^a   Flückiger, Jean Pierre ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MSDRL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; CNS; Huntington's disease; Malonate; Reversible caspase 3 inhibitor; Striatum

Indexed keywords

3 [[2 [[5 TERT BUTYL 3 [(4 METHYL 1,2,5 OXADIAZOL 3 YL)METHYL]AMINO] 2 OXOPYRAZIN 1(2H) YL]BUTANOYL]AMINO] 5 [HEXYL(METHYL)AMINO] 4 OXOPENTANOIC ACID; CASPASE 3 INHIBITOR; DIZOCILPINE; M 826; MALONIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; BRAIN TISSUE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG DIFFUSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ANALYSIS; ENZYME INHIBITION; HUNTINGTON CHOREA; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TITRIMETRY;

ANIMALS; AUTORADIOGRAPHY; CASPASE 3; CASPASES; CELL COUNT; CELL DEATH; DIFFUSION; DIZOCILPINE MALEATE; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; HALF-LIFE; HUNTINGTON DISEASE; MALE; MALONATES; NEOSTRIATUM; NEURONS; NEUROPROTECTIVE AGENTS; OXADIAZOLES; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 4544234691     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705662     Document Type: Article

References (46)

1. ALBIN, R.L. & TAGLE, D.A. (1995). Genetics and molecular biology of Huntington's disease. Trends Neurosci., 18, 11-14.
2. ANDREASSEN, O.A., FERRANTE, R.J., HUGHES, D.B., KLIVENYI, P., DEDEOGLU, A., ONA, V.O., FRIEDLANDER, R.M. & BEAL, M.F. (2000). Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. J. Neurochem., 75, 847-852.
3. ASHDOWN, H.J., ROY, S., ROBERTSON, G.S., NICHOLSON, D.W. & TOULMOND, S. (2002). Temporo-spatial distribution and cellular origin of caspase-3 and caspase-1, and their substrates huntingtin and IL-1, in the malonate model of neurodegeneration. Soc. Neurosci., 32, 198.9.
4. BEAL, M.F. (2000). Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci., 23, 298-304.
5. BEAL, M.F., BROUILLET, E., JENKINS, B., HENSHAW, R., ROSEN, B. & HYAMAN, B.T. (1993). Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem., 61, 1147-1150.
6. BILSLAND, J., ROY, S., XANTHOUDAKIS, S., NICHOLSON, D.W., HAN, Y., GRIMM, E., HEFTI, F. & HARPER, S.J. (2002). Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J. Neurosci., 22, 2637-2649.
7. BLOMGREN, K., ZHU, C., WANG, X., KARLSSON, J.-O., LEVERIN, A.-L., BAHR, B.A., MALLARD, C. & HAGBERG, H. (2001). Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia. J. Biol. Chem., 276, 10191-10198.
8. BROUILLET, E. (2000). Animal models of Huntington's disease: from basic research on neuronal death to assessment of new therapeutic strategies. Funct. Neurol., 15, 239-251.
9. BROUILLET, E., CONDE, F., BEAL, M.F. & HANTRAYE, P. (1999). Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol., 59, 427-468.
10. CATTANEO, E., RIGAMONTI, D., GOFFREDO, D., ZUCCATO, C., SQUITIERI, F. & SIPIONE, S. (2001). Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci., 24, 182-188.
11. CHAMBERS, J.M., CLEVELAND, W.S., KLEINER, B. & TUKEY, P.A. (1983). Graphical Methods for Data Analysis. Monterey, CA: Wadsworth.
12. CHEN, M., ONA, V.O., LI, M., FERRANTE, R.J., FINK, K.B., ZHU, S., BIAN, J., GUO, L., FARRELL, L.A., HERSCH, S.M., HOBBS, W., VONSATTEL, J.P., CHA, J.H. & FRIEDLANDER, R.M. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 6, 797-801.
13. CONCHA, N.O. & ABDEL-MEGUID, S.S. (2002). Controlling apoptosis by inhibition of caspases. Curr. Med. Chem., 9, 713-726.
14. DAVOLI, M.A., FOURTOUNIS, J., TAM, J., XANTHOUDAKIS, S., NICHOLSON, D., ROBERTSON, G. & XU, D. (2002). Immunohistochemical and biochemical assessment of caspase-3 activation and DNA fragmentation following transient focal ischemia in the rat. Neuroscience, 115, 125-136.
15. ENDRES, M., NAMURA, S., SHIMIZU-SASAMATA, M., WAEBER, C., ZHANG, L., GOMEZ-ISLA, T., HYMAN, B.T. & MOSKOWITZ, M.A. (1998). Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J. Cereb. Blood Flow Metab., 18, 238-247.
16. FOSTER, A.C., GILL, R. & WOODRUFF, G.N. (1988). Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed neurodegeneration mediated by NMDA receptor activation. J. Neurosci., 8, 4745-4754.
17. FRIEDLANDER, R.M. & YUAN, J. (1998). ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ., 5, 823-831.
18. GARCIA-CALVO, M., PETERSON, E.P., LEITING, B., RUEL, R., NICHOLSON, D.W. & THORNBERRY, N.A. (1998). Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem., 273, 32608-32613.
19. GILL, R., SORIANO, M., BLOMGREN, K., HAGBERG, H., WYBRECHT, R., MISS, M.-T., HOEFER, S., ADAM, G., NIEDERHAUSER, O., KEMP, J.A. & LOETSCHER, H. (2002). Role of caspase-3 in cerebral ischemia-induced neurodegeneration in adult and neonatal brain. J. Cereb. Blood Flow Metab., 22, 420-430.
20. GOLDBERG, Y.P., NICHOLSON, D.W., RASPER, D.M., KALCHMAN, M.A., KOIDE, H.B., GRAHAM, R.K., BROMM, M., KASEMI-ESFARJANI, P., THORNBERRY, N.A., VAILLANCOURT, J.P. & HAYDEN, M.R. (1996). Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet., 13, 442-449.
21. HABERKORN, U., KINSCHEF, R., KRAMMER, P.H., MIER, W. & EISENHUT, M. (2001). Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone. Nuclear Med. Biol., 28, 793-798.
22. HAN, H.B., XU, D., CHOI, J., HAN, Y., XANTHOUDAKIS, S., ROY, S., TAM, J., VAILLANCOURT, J., COLUCCI, J., SIMAN, R., GIROUX, A., ROBERTSON, G.S., ZAMBONI, R., NICHOLSON, D.W. & HOLTZMAN, D.M. (2002). Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic injury. J. Biol. Chem., 277, 30128-30136.
23. IHAKA, R. & GENTLEMAN, R. (1996). R: a language for data analysis and graphics. J. Comput. Graphical Stat., 5, 299-314.
24. JOZA, N., KROEMER, G. & PENNINGER, J.M. (2002). Genetic analysis of the mammalian machinery. Trends Genet., 18, 142-149.
25. LEE, D., LONG, S.A., ADAMS, J.L., CHAN, G., VAIDYA, K.S., FRANCIS, T.A., KIKLY, K., WINKLER, J.D., SUNG, C.M., DEBOUCK, C., RICHARDSON, S., LEVY, M.A., DEWOLF JR, W.E., KELLER, P.M., TOMASZEK, T., HEAD, M.S., RYAN, M.D., HALTIWANGER, R.C., LIANG, P.H., JANSON, C.A., MCDEVITT, P.J., JOHANSON, K., CONCHA, N.O., CHAN, W., ABDEL-MEGUID, S.S., BADGER, A.M., LARK, M.W., NADEAU, D.P., SUVA, L.J., GOWEN, M. & NUTTALL, M.E. (2000). Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem., 275, 16007-16014.
26. LEE, D., LONG, S.A., MURRAY, J.H., ADAMS, J.L., NUTTAL, M.E., NADEAU, D.P., KIKLY, K., WINKLER, J.D., SUNG, C.M., RYAN, M.D., LEVY, M.A., KELLER, P.M. & DE WOLF, W.E. (2001). Potent and selective nonpeptide inhibitors of caspases 3 and 7. J. Med. Chem., 44, 2015-2026.
27. MARAGOS, W.F. & SILVERSTEIN, F.S. (1995). The mitochondrial inhibitor malonate enhances NMDA toxicity in the neonatal rat striatum. Brain Res. Dev. Brain Res., 88, 117-121.
28. MATTHEWS, R.T., KLIVENYI, P., MUELLER, G., YANG, L., WERMER, M., THOMAS, C.E. & BEAL, M.F. (1999). Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol., 157, 120-126.
29. ONA, V.O., LI, M., VONSATTEL, J.P., ANDREWS, L.J., KHAN, S.Q., CHUNG, W.M., FREY, A.S., MENON, A.S., LI, X.J., STIEG, P.E., YUAN, J., PENNEY, J.B., YOUNG, A.B., CHA, J.H. & FRIEDLANDER, R.M. (1999). Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature, 399, 263-267.
30. PAXINOS, G. & WATSON, C. (1986). The Rat Brain in Stereotaxic Co-ordinates. London, U.K.: Academic Press.
31. PEARSON, V.L., ROTHWELL, N.J. & TOULMOND, S. (1999). Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. Glia, 25, 311-323.
32. SALGAME, P., VARADHACHARY, A.S., PRIMIANO, L.L., FINCKE, J.E., MULLER, S. & MONESTIER, M. (1997). An ELISA for detection of apoptosis. Nucleic Acid Res., 25, 680-681.
33. SANCHEZ, I., XU, C.J., JUO, P., KAKIZAKA, A., BLENIS, J. & YUAN, J. (1999). Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron, 22, 623-633.
34. SCHULZ, J.B., HENSHAW, D.R., SIWEK, D., JENKINS, B.C., FERRANTE, R.J., CIPOLLONI, P.B., KOWALL, N.W., ROSEN, B.R. & BEAL, M.F. (1995). Involvement of free radicals in excitotoxicity in vivo. J. Neurochem., 64, 2239-2247.
35. SCHULZ, J.B., HUANG, P.L., MATTHEWS, R.T., PASSOV, D., FISHMAN, M.C. & BEAL, M.F. (1996). Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. J. Neurochem., 67, 430-433.
36. SCHULZ, J.B., WELLER, M., MATTHEWS, R.T., HENEKA, M.T., GROSCURTH, P., MARTINOU, J.C., LOMMATZSCH, J., VON COELLN, R., WULLNER, U., LOSCHMANN, P.A., BEAL, M.F., DICHGANs, J. & KLOCKGETHER, T. (1998). Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ., 5, 847-857.
37. THORNBERRY, N.A., RANO, T.A., PETERSON, E.P., RASPER, D.M., TIMKEY, T., GARCIA-CALVO, M., HOUTZAGER, V.M., NORDSTROM, P.A., ROY, S., VAILLANCOURT, J.P., CHAPMAN, K.T. & NICHOLSON, D.W. (1997). A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem., 272, 17907-17911.
38. TOULMOND, S., ASHDOWN, H.J., DEGEN, S., TANG, K., BUREAU, Y., ZHU, Y., ROZON J COLUCCI, J., GIROUX, Y., HAN, Y., ROY, S., ZAMBONI, R., NICHOLSON, D.W., ROBERTSON, G.S. & FLÜCKIGER, J.P. (2002). M826, a selective caspase-3 inhibitor, attenuates malonate-induced neuronal death. Soc. Neurosci., 32, 200.3.
39. VEZZANI, A., SERAFINI, R., STASI, M.A., CACCIA, S., CONTI, I., TRIDICCIO, R.V. & SAMANIN, R. (1989). Kinetics of MK801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J. Pharmacol. Exp. Ther., 249, 278-290.
40. WALLING, H.W., BALDASSARE, J.J. & WESTFALL, T.C. (1998). Molecular aspects of Huntington's disease. J. Neurosci. Res., 54, 301-308.
41. WELLINGTON, C.L., ELLERBY, L.M., HACKAM, A.S., MARGOLIS, R.L., TRIFIRO, M.A., SINGARAJA, R., MCCUTCHEON, K., SALVESEN, G.S., PROPP, S.S., BROMM, M., ROWLAND, K.J., ZHANG, T., RASPER, D., ROY, S., THORNBERRY, N., PINSKY, L., KAKIZUKA, A., ROSS, C.A., NICHOLSON, D.W., BREDESEN, D.E. & HAYDEN, M.R. (1998). Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem., 273, 9158-9167.
42. WELLINGTON, C.L., SINGARAJA, R., ELLERBY, L., SAVILL, J., ROY, S., LEAVITT, B., CATTANEO, E., HACKAM, A., SHARP, A., THORNBERRY, N., NICHOLSON, D.W., BREDESEN, D.E. & HAYDEN, M.R. (2000). Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J. Biol. Chem., 275, 19831-19838.
43. WILLIS, C.L., BRAZELL, C. & FOSTER, A.C. (1991). Plasma and CSF levels of dizocilpine (MK801) required for neuroprotection in the quinolate-injected rat striatum. Eur. J. Pharmacol., 196, 285-290.
44. ZEITLIN, S., LIU, J.P., CHAPMAN, D.L., PAPAIOANNOU, V.E. & EFSTRATIADIS, A. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet., 11, 155-163.
45. ZHANG, X., CHEN, J., GRAHAM, S.H., DU, L., KOCHANEK, P.M., DRAVIAM, R., GUO, F., NATHANIEL, P.D., SZABO, C., WATKINS, S.C. & CLARK, R.S. (2002). Intranuclear localization of apoptosis-inducing factor (AIF) and large scale nuclear fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J. Neurochem., 82, 181-191.
46. ZHU, C., QIU, L., WANG, X., HALLIN, U., CANDE, C., KROEMER, G., HAGBERG, H. & BLOMGREN, K. (2003). Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemia in the neonatal rat brain. J. Neurochem., 86, 306-317.